Eiko Lifesciences Limited reported a 34.98% year-on-year increase in consolidated net profit to ₹150.83 lakh for the quarter ended June 30, 2026 (Q1FY27). The Mumbai-based speciality chemicals company saw revenue from operations surge 56.36% YoY to ₹1,715.96 lakh, driven by robust demand in its core chemical business and expanding logistics operations. This growth trajectory signals strengthening operational efficiency despite rising material costs.

The Board of Directors approved the unaudited standalone and consolidated financial results on August 12, 2026, pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by statutory auditors PSV Jain & Associates. The company operates under a single business segment for standalone reporting but discloses two reportable segments—Speciality & Fine Chemicals and Logistics Services—in its consolidated statements.

Financial Performance Highlights

Consolidated revenue from operations rose to ₹1,715.96 lakh in Q1FY27, compared to ₹1,097.66 lakh in the same period last year. Standalone revenue also climbed significantly to ₹1,486.51 lakh from ₹800.60 lakh YoY. Total comprehensive income for the group stood at ₹150.83 lakh, up from ₹111.74 lakh in Q1FY26.

*Profit before exceptional items, share of profit in equity accounted investees, and tax for consolidated; Profit before exceptional items and tax for standalone.

Segment-Wise Breakdown

The Speciality & Fine Chemicals segment contributed ₹15.25.32 lakh to consolidated revenue, up from ₹8.40.22 lakh YoY, with segment results improving to ₹98.86 lakh from ₹44.42 lakh. The Logistics Services segment, operated through subsidiary Eikovivify Logistics Private Limited, generated ₹1.49.56 lakh in revenue, down slightly from ₹2.30.93 lakh YoY, but maintained stable segment results of ₹28.67 lakh.

Cost of materials consumed accounted for the largest expense head at ₹13.93.79 lakh (consolidated), reflecting higher input prices. However, favorable changes in inventories of finished stock and work-in-progress (-₹40.96 lakh) helped offset some cost pressures. Finance costs increased to ₹13.01 lakh from ₹4.82 lakh YoY, primarily due to higher borrowing levels supporting operational expansion.

What the Numbers Show

The divergence between standalone and consolidated growth rates reveals the impact of associate companies and subsidiaries on overall profitability. While standalone revenue nearly doubled YoY (+85.67%), consolidated revenue grew at a more moderate 56.36%, indicating that existing subsidiary operations are maturing while new initiatives scale. The significant improvement in inventory management—showing negative changes in both standalone (-₹40.96 lakh) and consolidated (-₹40.96 lakh) statements—suggests improved supply chain efficiency or deliberate stock drawdown strategies that positively impacted current-quarter margins.

Chairman Laxmikant Kabra noted that the results reflect strong execution across business verticals. The company’s paid-up equity share capital remains unchanged at ₹1,434.59 lakh, with no new issuances during the quarter. Earnings per share (basic) increased to ₹0.91 from ₹0.66 YoY on a consolidated basis, offering shareholders tangible value creation despite macroeconomic uncertainties in the chemical sector.

Eiko LifeSciences Limited reported a 106% year-on-year increase in net profit to ₹358.11 lakh for the financial year ended March 31, 2026. Revenue from operations rose 30% to ₹4,212.68 lakh, driven by the speciality chemicals and pharma intermediates segment. The board approved the audited standalone and consolidated financial results at its meeting on May 26, 2026.

The statutory auditor, PSV Jain & Associates, issued an unmodified opinion on the financial results. The board also appointed M/s NP Rajput & Co as the internal auditor for FY27.

Financial Performance

The company’s standalone total revenue for FY26 stood at ₹4,425.61 lakh, compared to ₹3,351.58 lakh in the previous year. Total expenses increased to ₹3,954.31 lakh from ₹3,153.88 lakh. Basic earnings per share (EPS) for the year doubled to ₹2.60 from ₹1.34 in the prior year.

On a consolidated basis, net profit for FY26 surged 130% to ₹532.47 lakh from ₹231.86 lakh in FY25. Consolidated revenue from operations grew 40% to ₹5,270.66 lakh. The company’s subsidiary, Eikovivify Logistics Private Limited, commenced operations during the year, contributing to the logistics services segment.

Capital Allocation

Pursuant to shareholder approval in January 2026, the company allotted 6,25,000 equity shares and 29,50,000 warrants. The equity shares were issued at ₹55 per share, including a premium of ₹45. The proceeds strengthened the balance sheet, with cash and cash equivalents increasing to ₹1,355.16 lakh as of March 31, 2026.

The trading window for directors and designated persons, which closed on April 1, 2026, will reopen 48 hours after the declaration of the financial results.